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As the overall incidence of lung cancer in-
creases, SCLC represents a growing global health
problem, despite the fact that the proportion of
lung cancers of small cell histology has dimi-
nished in recent years. Within the EU, the inci-
dence of cigarette smoking amongst women and
youngsters continues to rise, and there will be a
consequent and tragic epidemic of lung cancers
of all histologies, including SCLC, over the next
20 to 40 years. The most important aspects of
disease management are prevention and early
detection, and the role of the health care profes-
sional in these is crucial. For patients with esta-
blished SCLC, however, optimal chemotherapy,
plus consolidation radiotherapy in selected pa-
tients, is the mainstay of therapy. Optimal chemo-
therapy prolongs the survival of patients whilst
maintaining or improving the quality of life.
Regrettably, however, the huge majority of
patients will experience relapse following first
line therapy. Once the disease has relapsed, it is
deemed to be incurable and the principle objec-
tive of second line therapy is the palliation of
symptoms with prolongation of survival as an
important, but secondary, objective. Both of these
objectives can be achieved with appropriate
therapy, and re-treatment of patients at relapse
after optimal first line therapy is established prac-
tice within the European Union. In a randomised
study against CAV, topotecan has been shown to
be efficacious in the management of relapsed,
sensitive SCLC. Topotecan was associated with
survival rates that were at least as good as those
associated with CAV, and, in addition for 8 out
of 9 symptoms evaluated, topotecan was asso-
ciated with numerically superior symptom pal-
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liation compared to CAV. For 5 of the 9 symp-
toms evaluated, the p values were < 0.05 in fa-
vour of topotecan. Furthermore, topotecan can
penetrate the intact blood brain barrier and is ac-
tive against brain metastases. Topotecan has the
advantage of good tolerability from the patient’s
point of view, but is given as a short infusion on
each of 5 consecutive days, repeated every 3
weeks. To improve the convenience of adminis-
tration, weekly delivery of topotecan is being in-
vestigated; and an oral formulation is under de-
velopment.
